dr. rule on standard of care in mcl
Published 5 years ago • 92 plays • Length 2:00Download video MP4
Download video MP3
Similar videos
-
1:29
dr. rule on the treatment paradigm in mcl
-
0:59
dr. rule on the fda approval of zanubrutinib in mcl
-
0:57
dr. rule on treatment of young, fit patients with mcl
-
1:23
dr. rule on the future treatment paradigm in mcl
-
1:26
dr. rule addresses questions on the watch-and-wait approach in mcl
-
10:04
mantle cell lymphoma for newly diagnosed patients
-
13:17
mantle cell lymphoma: latest treatments | dr. david miklos, stanford | the patient story
-
12:38
mantle cell lymphoma research and clinical trials
-
1:56
dr. rule on the role of btk inhibitors in mcl
-
1:02
dr. goy on the progression of mcl treatment
-
2:06
dr. rule on watching and waiting approach for mcl subset
-
1:28
dr. rule on potential for car t-cell therapy in mcl
-
1:22
dr. rule on searching for a biomarker indicating indolent mcl
-
1:28
dr. goy on the evolution of treatment selection in mcl
-
0:55
dr. wang on the evolution of treatment in mcl
-
1:36
dr. rule on long-term follow-up of ibrutinib monotherapy in relapsed/refractory mcl
-
1:27
dr. rule on the combination of venetoclax and ibrutinib in mcl
-
2:44
standard of care treatment approaches in mcl and the role of chemotherapy-free regimens
-
1:33
dr. jacobs on the efficacy of ibrutinib and acalabrutinib in patients with mcl
-
1:03
advancements in mcl treatment
-
1:22
dr. ruan on unanswered questions regarding treatment decisions in mcl
-
0:48
real-world results in the uk for ibrutinib at first relapsed for mcl